Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Total Debt (2016 - 2025)

Guided Therapeutics' Total Debt history spans 14 years, with the latest figure at $108000.0 for Q3 2025.

  • For Q3 2025, Total Debt fell 90.87% year-over-year to $108000.0; the TTM value through Sep 2025 reached $108000.0, down 90.87%, while the annual FY2024 figure was $165000.0, N/A changed from the prior year.
  • Total Debt for Q3 2025 was $108000.0 at Guided Therapeutics, up from $95000.0 in the prior quarter.
  • Across five years, Total Debt topped out at $1.2 million in Q2 2024 and bottomed at $32000.0 in Q3 2022.
  • The 4-year median for Total Debt is $157000.0 (2022), against an average of $427500.0.
  • The largest YoY upside for Total Debt was 1145.1% in 2022 against a maximum downside of 94.7% in 2022.
  • A 4-year view of Total Debt shows it stood at $680000.0 in 2021, then tumbled by 85.29% to $100000.0 in 2022, then surged by 65.0% to $165000.0 in 2024, then crashed by 34.55% to $108000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Total Debt are $108000.0 (Q3 2025), $95000.0 (Q2 2025), and $107000.0 (Q1 2025).